(Q35688238)

9 August 2017

1 reference

title

Camptothecins in clinical development (English)

1 reference

9 August 2017

Franco Zunino

1

1 reference

9 August 2017

Graziella Pratesi

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

published in

1 reference

9 August 2017

volume

13

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

269-284

1 reference

Topoisomerase I poisons and suppressors as anticancer drugs

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Current status and perspectives in the development of camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Cellular roles of dna topoisomerases: a molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

The cell cycle effects of camptothecin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Cellular resistance to camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Irinotecan (Campto®) in the treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Optimizing the use of irinotecan in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Novel 7-substituted camptothecins with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Effective drug delivery by PEGylated drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

20-O-acylcamptothecin derivatives: evidence for lactone stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

Perspectives in camptothecin development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.269

10.1517/13543784.13.3.269

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference